Seis cesto carro

Informação básica

• Disponível em:
• English
• Português

The EarlyTect Colon Cancer Test is a groundbreaking product that has been approved by the Korea Ministry of Food and Drug Safety. It has undergone rigorous clinical trials at prestigious medical centers such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center. The trials involved 585 participants, both men and women aged 30 to 80.

Through these clinical trials, it has been demonstrated that the EarlyTect Colon Cancer Test has a remarkable accuracy rate of 90% in diagnosing colorectal cancer (CRC). Specifically, it uses fecal DNA analysis to detect methylated Syndecan-2, a biomarker that is closely linked to precancerous lesions of CRC.

It is important to note that the EarlyTect Colon Cancer Test is a qualitative real-time PCR test, meaning it provides reliable results in a timely manner. However, it is not intended to confirm the presence of colorectal cancer itself. Instead, it is designed for screening purposes, allowing doctors to identify individuals who may have CRC or precancerous lesions of CRC.

The product adheres to a specific set of standards, which include the following:

- Cancer Type: Colorectal Cancer
- Subject: Asymptomatic individuals undergoing colorectal cancer screening
- Biomarker: SDC2 methylation

The price and transaction conditions for the EarlyTect Colon Cancer Test are negotiable. To get detailed information on pricing and initiate a transaction, please kindly request a quote.

Thank you for your interest in the EarlyTect Colon Cancer Test. We believe it is a crucial tool in the early detection and prevention of colorectal cancer.